MIF and colorectal carcinoma: High expression of MIF in KRAS mutant CRC cells activates STAT3 and MAPK, which upregulate cyclin D1 expression and reduce caspase 3 activity, resulting in resistance of CRC cells to the MEK blocker refametinib [94].